Clearmind Medicine Begins Third Cohort Recruitment for CMND-100 AUD Trial at Yale, Johns Hopkins
CMND is trading near its 52-week low of $0.97 (9.3% above the low).
Summary
Clearmind Medicine Inc. announced it is advancing recruitment for the third cohort of its CMND-100 Phase I/IIa clinical trial for Alcohol Use Disorder (AUD) at sites including Yale and Johns Hopkins. This operational step follows the positive topline results from the second cohort and the Data and Safety Monitoring Board's (DSMB) approval to continue the trial, which was previously reported on March 4th. For this micro-cap biotech, the progression to active recruitment for the next cohort is a material positive development, demonstrating execution and continued confidence in its lead drug candidate. Investors will be watching for updates on patient enrollment and future data readouts from this ongoing trial.
At the time of this announcement, CMND was trading at $1.06 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5M. The 52-week trading range was $0.97 to $52.40. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.